Overview

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2

Status:
Completed

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

A randomized, placebo-controlled, double-blind, parallel group, multi-center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) subjects recovering from hospitalization for an acute exacerbation (Hospital Discharge Study 2)

Phase:

Phase 4

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Bromides
Tiotropium Bromide